JPH01294667A - Thiazole derivative - Google Patents
Thiazole derivativeInfo
- Publication number
- JPH01294667A JPH01294667A JP63125471A JP12547188A JPH01294667A JP H01294667 A JPH01294667 A JP H01294667A JP 63125471 A JP63125471 A JP 63125471A JP 12547188 A JP12547188 A JP 12547188A JP H01294667 A JPH01294667 A JP H01294667A
- Authority
- JP
- Japan
- Prior art keywords
- added
- compound
- purity
- yield
- cephem
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000007979 thiazole derivatives Chemical class 0.000 title 1
- -1 2-(2-tritylaminothiazol-4-yl)-2 -Methoxyiminoacetic acid lithium salt Chemical compound 0.000 claims description 9
- 150000004677 hydrates Chemical class 0.000 claims 1
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 abstract description 12
- 229910003002 lithium salt Inorganic materials 0.000 abstract description 7
- 229930186147 Cephalosporin Natural products 0.000 abstract description 5
- 229940124587 cephalosporin Drugs 0.000 abstract description 5
- 125000005907 alkyl ester group Chemical group 0.000 abstract description 4
- 230000003115 biocidal effect Effects 0.000 abstract description 4
- 150000001780 cephalosporins Chemical class 0.000 abstract description 4
- 239000000126 substance Substances 0.000 abstract description 3
- 230000003301 hydrolyzing effect Effects 0.000 abstract description 2
- 239000000463 material Substances 0.000 abstract description 2
- HQOQSFITXGQQDM-SSDOTTSWSA-N methyl (6R)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical compound COC(=O)C1=CCS[C@@H]2CC(=O)N12 HQOQSFITXGQQDM-SSDOTTSWSA-N 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 238000001914 filtration Methods 0.000 description 13
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 12
- 239000002244 precipitate Substances 0.000 description 11
- 238000003756 stirring Methods 0.000 description 11
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 8
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 8
- 238000001816 cooling Methods 0.000 description 8
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 7
- 239000003242 anti bacterial agent Substances 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 159000000000 sodium salts Chemical class 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 238000001291 vacuum drying Methods 0.000 description 6
- 229940088710 antibiotic agent Drugs 0.000 description 5
- 159000000002 lithium salts Chemical class 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 150000001782 cephems Chemical group 0.000 description 4
- 238000002329 infrared spectrum Methods 0.000 description 4
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 4
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical group C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical group C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- QQVDYSUDFZZPSU-UHFFFAOYSA-M chloromethylidene(dimethyl)azanium;chloride Chemical compound [Cl-].C[N+](C)=CCl QQVDYSUDFZZPSU-UHFFFAOYSA-M 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- PQVSTLUFSYVLTO-UHFFFAOYSA-N ethyl n-ethoxycarbonylcarbamate Chemical compound CCOC(=O)NC(=O)OCC PQVSTLUFSYVLTO-UHFFFAOYSA-N 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000009776 industrial production Methods 0.000 description 2
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium hydroxide monohydrate Substances [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 2
- 229940040692 lithium hydroxide monohydrate Drugs 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- VIKZIPIQNIJTFL-WMZJFQQLSA-N (2z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetamide Chemical compound CO\N=C(/C(N)=O)C1=CSC(N)=N1 VIKZIPIQNIJTFL-WMZJFQQLSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- PKPGSMOHYWOGJR-UHFFFAOYSA-N 2-methoxyimino-2-[2-(tritylamino)-1,3-thiazol-4-yl]acetic acid Chemical compound CON=C(C(O)=O)C1=CSC(NC(C=2C=CC=CC=2)(C=2C=CC=CC=2)C=2C=CC=CC=2)=N1 PKPGSMOHYWOGJR-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
- 241000270666 Testudines Species 0.000 description 1
- OXDRBKKGZFUHSW-UHFFFAOYSA-M [Na+].CON=C(C([O-])=O)C1=CSC(NC(C=2C=CC=CC=2)(C=2C=CC=CC=2)C=2C=CC=CC=2)=N1 Chemical compound [Na+].CON=C(C([O-])=O)C1=CSC(NC(C=2C=CC=CC=2)(C=2C=CC=CC=2)C=2C=CC=CC=2)=N1 OXDRBKKGZFUHSW-UHFFFAOYSA-M 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 150000002736 metal compounds Chemical class 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- DOOVDXPRGGINTD-UHFFFAOYSA-N methyl 2-methoxyiminoacetate Chemical compound CON=CC(=O)OC DOOVDXPRGGINTD-UHFFFAOYSA-N 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 238000000634 powder X-ray diffraction Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000013076 target substance Substances 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Landscapes
- Cephalosporin Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Abstract
Description
【発明の詳細な説明】
〈産業上の利用分野〉
本発明は、セファロスポリン系抗生物質1例えば、7β
−[2−(2−アミノチアゾール−4−イル)−2−メ
トキシイミノアセトアミド] −3−[4−オキサゾー
ル−5−イル−1−ピリジニオコメチル−3−セフェム
−4−カルボキシレートを製造するたの新規合成中間体
間するものである。Detailed Description of the Invention <Industrial Application Field> The present invention provides cephalosporin antibiotics 1, such as 7β
-[2-(2-Aminothiazol-4-yl)-2-methoxyiminoacetamide] -Produces -3-[4-oxazol-5-yl-1-pyridiniocomethyl-3-cephem-4-carboxylate This is among the new synthetic intermediates.
上記の化合物は、特開昭61−7280号に、グラム陰
性、グラム陽性両画全般に幅広い抗菌スペクトルを有す
るのみならず、 !im菌に対しても強い活性を示し、
抗生物質として極めて有望であることが開示されている
。The above compound not only has a broad antibacterial spectrum in both gram-negative and gram-positive categories, but also has a broad antibacterial spectrum as described in JP-A-61-7280. It also shows strong activity against im bacteria,
It has been disclosed that it is very promising as an antibiotic.
〈従来技術〉
セフ10スポリン系抗生物買の分野においては、化学構
造の複雑さから製造コストが窩むので、新規で有効な製
造方法について常に模索させている。特に製造原料の選
択は、目的とする抗生物質の経済的かつ工業的生産とい
う観点から重要な問題である。<Prior Art> In the field of cef-10-sporin antibiotics, manufacturing costs are high due to the complexity of their chemical structures, so new and effective manufacturing methods are constantly being sought. In particular, the selection of raw materials for production is an important issue from the viewpoint of economical and industrial production of the target antibiotic.
これに関連して、特開昭52−102.293号には、
セファロスポリン系化合物の製造中間体として、 2−
(2−トリチルアミノチアゾール−4−イル)−2−メ
トキシイミノ酢酸(1’)およびそのナトリウム塩が記
載されており、遊離体はナトリウム塩を酸にて中和する
こと(より製造されている。In this regard, JP-A-52-102.293 states:
As an intermediate for the production of cephalosporin compounds, 2-
(2-tritylaminothiazol-4-yl)-2-methoxyiminoacetic acid (1') and its sodium salt are described, and the free form can be obtained by neutralizing the sodium salt with acid (it is produced by .
そこで、製造中間体として経済的に有利な化合物(1)
のナトリウム塩を用い、一方の原料である下記化合物(
11)との反応を試みたが、純度及び収率の点で必ずし
も潰延すべき結果が得られなかった。Therefore, compound (1) is economically advantageous as a manufacturing intermediate.
Using the sodium salt of one of the raw materials, the following compound (
Although attempts were made to react with 11), no satisfactory results were obtained in terms of purity and yield.
〈発明が解決しようとする問題点〉
本発明者らは、上記欠点を克服すべく、化合物(I)の
塩類について鋭意検討した結果、そのリチウム塩がナト
リウム塩等に比べ、セファロスポリン系抗生物質の製造
において9例えば、化合物(!K)のホウフッ化物、ホ
ウフッ化水素酸塩と反応させた場合、非常に優れた反応
制を有し、かつ得られた抗生物質の純度もはるかに優れ
たものであることを見い出し1本発明を完成した。<Problems to be Solved by the Invention> In order to overcome the above-mentioned drawbacks, the present inventors have made extensive studies on the salts of compound (I), and have found that the lithium salt is more effective against cephalosporin antibiotics than the sodium salt, etc. 9 For example, when the compound (!K) is reacted with borofluoride or borohydrofluoride in the production of substances, it has very good reaction control and the purity of the obtained antibiotic is also much better. Based on this discovery, the present invention was completed.
〈発明の構成〉
本発明の化合物は次の方法により容易に製造することが
できる。すなわち化合物(1)の低級アルキルエステル
体を水酸化リチウムの存在下に加水分解することにより
製造される。<Structure of the Invention> The compound of the present invention can be easily produced by the following method. That is, it is produced by hydrolyzing a lower alkyl ester of compound (1) in the presence of lithium hydroxide.
この反応は、水を含む溶媒中で行われ、溶媒としては、
メタノール、エタノール、イソプロピルアルコール等の
アルコール類、ジオキサン、テトラヒドロフラン等のエ
ーテル類、または、その他の反応に悪影響を及ぼさない
すべての溶媒が挙げられる。溶媒の使用量は特に限定さ
れないが、化金物(1)の低級アルキルエステル体1部
に対して4部以上が好適である。This reaction is carried out in a solvent containing water, and the solvent is
Examples include alcohols such as methanol, ethanol, and isopropyl alcohol, ethers such as dioxane and tetrahydrofuran, and all other solvents that do not adversely affect the reaction. Although the amount of the solvent used is not particularly limited, it is preferably 4 parts or more per 1 part of the lower alkyl ester of metal compound (1).
使用される水酸化リチウムとしては無水物又は水和物の
どちらでも良く、また、水溶液として使用しても良い、
かかる水酸化リチウムの使用量は化合物(I)の低級ア
ルキルエステル体に対して等モル以上あれば充分である
。The lithium hydroxide used may be either anhydrous or hydrated, or may be used as an aqueous solution.
It is sufficient that the amount of lithium hydroxide used is at least equimolar to the lower alkyl ester of compound (I).
反応温度は特に限定されないが1通常、加熱下に行われ
ることが多い。かくして反応後、析出物を室温又は冷却
下濾取することにより、高収率且つ高純度に目的物を得
ることができる。Although the reaction temperature is not particularly limited, it is usually carried out under heating. After the reaction, the desired product can be obtained in high yield and purity by filtering the precipitate at room temperature or under cooling.
〈発明の効果〉
本発明の目的物質は必要があれば精製しても良いが、精
製することなく、ビルスマイヤー試薬と処理して活性体
を形成させた後、化合物(!■)と縮合させ、続いて保
護基を除去することにより最終のセファロボリン誘導体
を収率良く得ることができる。尚、上記活性体は濾過す
ることによって単離することも可能であり、Jullt
t、た活性体と化合物(II)を上記と同様な縮合・脱
保護条件下に反応させると、収率・純度共良好に最終セ
ファロボリン誘導体を得ることができる(収率86〜8
9零。<Effects of the Invention> The target substance of the present invention may be purified if necessary, but instead of being purified, it can be treated with Vilsmeier reagent to form an active substance, and then condensed with the compound (!■). By subsequently removing the protecting group, the final cephaloborin derivative can be obtained in good yield. Incidentally, the above-mentioned active substance can also be isolated by filtration.
When the active form of t, and compound (II) are reacted under the same condensation and deprotection conditions as above, the final cephaloborin derivative can be obtained with good yield and purity (yield: 86-8
9 zero.
純度76〜87零)。Purity 76-87 zero).
一方、ナトリウム塩は上記と同様の条件によるビルスマ
イヤー試薬との活性化反応に於いて、副生成物が多く、
その活性体を単離することは困難であり、続く、化合物
(II)との縮合・脱保護反応により、最終セファロボ
リン誘導体に導いたところ充分に良い結果は得られず(
収率76零、純度72%)、最終物質の精製に困難が伴
った。On the other hand, the sodium salt produces many by-products in the activation reaction with the Vilsmeier reagent under the same conditions as above.
It was difficult to isolate the active form, and when the final cephaloborin derivative was obtained through the subsequent condensation and deprotection reaction with compound (II), sufficiently good results were not obtained (
(yield: 760, purity: 72%), but there were difficulties in purifying the final material.
一般にセファロスポリン系抗生物質は安定性に乏しく1
分解し易いので、若干でも収率・純度の高い枢体を得る
ことは、工業的に非常に価値が大である。従って、ナト
リウム塩に代えてリチウム塩を使用した場合、上述の収
率・純度の改善が認められたということは、抗生物質の
工業的生産及び経済性において極めて重要な成果といえ
る。In general, cephalosporin antibiotics have poor stability1
Since it is easy to decompose, it is of great industrial value to obtain even a slightly higher yield and purity of the cardinal. Therefore, the fact that the above-mentioned improvement in yield and purity was observed when a lithium salt was used instead of a sodium salt can be said to be an extremely important result in terms of industrial production and economic efficiency of antibiotics.
以下実施例及び参考例にて本発明を説明する。The present invention will be explained below with reference to Examples and Reference Examples.
[実施例1]
2−(2−トリチルアミノチアゾール−4−イル −2
−メトキシイミノ 酸リチウム塩、 syn 性体’
2−(2−トリチルアミノチアゾール−4−イル)
−2−メトキシイミノ酢酸メチルエステル23.0gに
100 o+1のイソプロピルアルコールを加えて攪拌
し、加温して溶解した。この溶液に水10m1に溶解し
た水酸化リチウム・1水和物2.52gの水溶液を加え
た。還流温度で2.5時間攪拌後1反応液を冷却して、
析出物を濾取した。濾過物をイソプロピルアルコールに
て洗浄後、真空乾燥して標題化合物を92零の収率で得
た(純度96k)。[Example 1] 2-(2-tritylaminothiazol-4-yl-2
-Methoxyimino acid lithium salt, syn form'
2-(2-tritylaminothiazol-4-yl)
100 o+1 isopropyl alcohol was added to 23.0 g of -2-methoxyiminoacetic acid methyl ester, stirred, and dissolved by heating. To this solution was added an aqueous solution of 2.52 g of lithium hydroxide monohydrate dissolved in 10 ml of water. After stirring at reflux temperature for 2.5 hours, one reaction solution was cooled,
The precipitate was collected by filtration. The filtrate was washed with isopropyl alcohol and dried under vacuum to obtain the title compound in a yield of 920 (purity 96k).
定量は高速液体クロマトグラフィーを使用し。Quantification was performed using high performance liquid chromatography.
下記の条件下行った。It was conducted under the following conditions.
カラム: YMCpacked column A−3
12(ODS)6.0φX 150mm
検 出: UV 254nm
チウム塩)
FT−NMR(90MHz、DMSO−da、δ、pp
m) :3.64(3H,s、メトキシ基)
6.57(IH,s、チアゾール環5位のH)7.32
(15H,s、 )−リチル基のH)8.89(1
)1.S、チアゾール環2位のアミノ基のH)元素分析
C25H2゜N、0.SLi・3/4H,Oに対して理
論値 C64,86,H4,6B、 H9,0M分析値
C64,89,H4,95,H9,)3得られた2−
(2−トリチルアミノチアゾール−4−イル)−2−メ
トキシイミノ酢酸リチウム塩の結晶はニッケルをフィル
ターとするλ= 1.5418Aの銅X線を用いた粉末
X線回折[d−格子面間隔]が以下の特性を示す。Column: YMCpacked column A-3
12 (ODS) 6.0φX 150mm Detection: UV 254nm lithium salt) FT-NMR (90MHz, DMSO-da, δ, pp
m): 3.64 (3H, s, methoxy group) 6.57 (IH, s, H at 5-position of thiazole ring) 7.32
(15H,s, )-H of lythyl group) 8.89 (1
)1. S, H) Elemental analysis of the amino group at the 2-position of the thiazole ring C25H2°N, 0. Theoretical value C64,86, H4,6B, H9,0M analysis value C64,89, H4,95, H9,)3 obtained 2-
Crystals of lithium salt of (2-tritylaminothiazol-4-yl)-2-methoxyiminoacetate were analyzed by powder X-ray diffraction using copper X-rays with λ = 1.5418A using a nickel filter [d-lattice spacing] shows the following characteristics.
Uニー 」−−lユ
17.74 VS 5.29 w13.
93 S 4.51
s7.63 5 4.47 m7.27
S 4.35胃
8.92 m 4.25
s6.37 ta 3.96 s
5.95 s 3.72冑
但し0表中、Sは「強J、mは「中等度J、Wは「弱」
そしてVは「非常に」をそれぞれ意味する。Unie”--l Yu17.74 VS 5.29 w13.
93 S 4.51
s7.63 5 4.47 m7.27
S 4.35 Stomach 8.92 m 4.25
s6.37 ta 3.96 s
5.95 s 3.72 冑However, in the table, S stands for "strong J", m stands for "moderate J", and W stands for "weak".
And V means "very".
[実施例2]
2−(2−トリチルアミノチアゾール−4−イル)−2
−メトキシイミノ酢酸メチルエステル11.5gに50
1のメタノールを加えて攪拌し、加温して溶解した。こ
の溶液に水5mJ2に溶解した水酸化リチウム・1水和
物1.26gの水溶液を加えた。還流温度で2.5時間
攪拌する。析出晶を濾取し、メタノールにて洗浄後、真
空乾燥して標題化合物を77にの収率で得た(純度97
k)。[Example 2] 2-(2-tritylaminothiazol-4-yl)-2
-50 to 11.5 g of methoxyiminoacetic acid methyl ester
1 of methanol was added, stirred, and dissolved by heating. To this solution was added an aqueous solution of 1.26 g of lithium hydroxide monohydrate dissolved in 5 mJ2 of water. Stir at reflux temperature for 2.5 hours. The precipitated crystals were collected by filtration, washed with methanol, and dried under vacuum to obtain the title compound in a yield of 77% (purity: 97%).
k).
得られた化合物のIR及びNMRスペクトルは実施例1
で得られたものと一致した。The IR and NMR spectra of the obtained compound are as shown in Example 1.
It was consistent with what was obtained.
[参考例1]
アセトニトリル13.8mlとジメチルアセトアミド0
.77m1の混液を氷冷し、オキシ塩化リン0.77m
1を加えて同温30分間攪拌後−20℃に冷却し、 2
−(2−トリチルアミノチアゾール−4−イル)−2−
メトキシイミノ酢酸リチウム塩1.25gを加え、同温
30分間攪拌した。トリエチルアミン1.73n+1.
次いで7β−アミノ−3−[4−(オキサゾール−5−
イル)−1−ピリジニオコメチル−3−セフェム−4−
カルボン酸p−メトキシベンジルエステルホウフッ化物
ホウフッ化水素酸塩1.70gを加えた。水冷で30分
間攪拌後1反応液を水に注加し、析出物を濾取した。[Reference Example 1] 13.8 ml of acetonitrile and 0 of dimethylacetamide
.. Cool 77ml of the mixture on ice, and add 0.77ml of phosphorus oxychloride.
Add 1 and stir for 30 minutes at the same temperature, then cool to -20°C,
-(2-tritylaminothiazol-4-yl)-2-
1.25 g of lithium methoxyiminoacetate was added and stirred at the same temperature for 30 minutes. Triethylamine 1.73n+1.
Then 7β-amino-3-[4-(oxazole-5-
yl)-1-pyridiniocomethyl-3-cephem-4-
1.70 g of carboxylic acid p-methoxybenzyl ester borofluoride borohydrofluoride was added. After stirring for 30 minutes under water cooling, one reaction solution was poured into water, and the precipitate was collected by filtration.
真空乾燥して得られた粉末にトリフロロ酢酸30m1と
アニソール3mlを加え、水冷2時間攪拌した。30 ml of trifluoroacetic acid and 3 ml of anisole were added to the powder obtained by vacuum drying, and the mixture was stirred for 2 hours under water cooling.
反応後、イソプロピルエーテル901を加え、析出物を
濾取し、イソプロピルエーテルで洗浄した後、真空乾燥
して標題化合物を86零の収率で得た(純度77!k)
、 定量は高速液体クロマトグラフィーを使用し、下
記の条件下行った。After the reaction, isopropyl ether 901 was added, and the precipitate was collected by filtration, washed with isopropyl ether, and dried under vacuum to obtain the title compound in a yield of 860 (purity 77!k).
, Quantification was performed using high performance liquid chromatography under the following conditions.
カラム: YMCpacked column^−31
2(ODS)6.0φx 150m+a
検 出: UV 254nm
FT−NMR(90MHz、D、0. δ、ppm)
:3.3B、 3.83(2H,ABq、 J−1
8Hz、セフェム環2位のH)
4.06(3H,s、メトキシ基)
5.36(IH,d、J−5)1z、セフェム環6位の
H)5.38.5.82(2H,^Bq、J=15Hz
、セフェム環3位のCH2基のH)
5.90(IH,d、J=5Hz、セフェム環7位のH
)7.13(IH,s、チアゾール環5位のH)8.2
1(1M、s、オキサゾール環4位のH)8.56(I
H,s、オキサゾール環2位のH)8.34.8.98
(各々2H,各々d、 J=7Hz、ピリジン環のH
)
[参考例2]
−ルー5−イル −1−ピリジニオ メチル−3−セフ
エム−4−カルボキシレート トリフロロ 塩アセト
ニトリル13.8g+1とジメチルアセトアミド0.7
7m1の混液を氷冷し、オキシ塩化リン0.77m1を
加えて、同温30分間攪拌後−20℃に冷却し、 2−
(2−トリチルアミノチアゾール−4−イル)−2−メ
トキシイミノ酢酸ナトリウム塩1.29gを加え、同温
30分間攪拌した。トリエチルアミン1.73m1.次
いで7β−アミノ−3−[4−(オキサゾール−5−イ
ル)−1−ピリジニオコメチル−3−セフェム−4−カ
ルボン酸p−メトキシベンジルエステルホウフッ化物ホ
ウフッ化水素酸塩1.70gを加えた。水冷で30分間
攪拌後1反応液を水に注加し、析出物を濾取した。真空
乾燥して得られた粉末にトリフロロ酢酸30m1とアニ
ソール3mlを加え、水冷2時間攪拌した0反応後、イ
ソプロピルエーテル9On+1を加え。Column: YMCpacked column^-31
2 (ODS) 6.0φx 150m+a Detection: UV 254nm FT-NMR (90MHz, D, 0. δ, ppm)
:3.3B, 3.83(2H, ABq, J-1
8Hz, H at the 2nd position of the cephem ring) 4.06 (3H, s, methoxy group) 5.36 (IH, d, J-5) 1z, H at the 6th position of the cephem ring) 5.38.5.82 (2H , ^Bq, J=15Hz
, H of the CH2 group at the 3rd position of the cephem ring) 5.90 (IH, d, J = 5Hz, H of the CH2 group at the 7th position of the cephem ring)
) 7.13 (IH, s, H at position 5 of thiazole ring) 8.2
1 (1M, s, H at position 4 of oxazole ring) 8.56 (I
H, s, H at position 2 of oxazole ring) 8.34.8.98
(2H each, d each, J=7Hz, H of pyridine ring
) [Reference Example 2] -R-5-yl -1-pyridinio methyl-3-cephem-4-carboxylate trifluoro salt Acetonitrile 13.8g+1 and dimethylacetamide 0.7
7 ml of the mixed liquid was ice-cooled, 0.77 ml of phosphorous oxychloride was added, and after stirring at the same temperature for 30 minutes, it was cooled to -20°C. 2-
1.29 g of (2-tritylaminothiazol-4-yl)-2-methoxyiminoacetic acid sodium salt was added and stirred at the same temperature for 30 minutes. Triethylamine 1.73ml1. Then, 1.70 g of 7β-amino-3-[4-(oxazol-5-yl)-1-pyridiniocomethyl-3-cephem-4-carboxylic acid p-methoxybenzyl ester borofluoride borohydrofluoride was added. Ta. After stirring for 30 minutes under water cooling, one reaction solution was poured into water, and the precipitate was collected by filtration. 30 ml of trifluoroacetic acid and 3 ml of anisole were added to the powder obtained by vacuum drying, and after cooling with water and stirring for 2 hours, 9On+1 of isopropyl ether was added.
析出物を濾取し、イソプロピルエーテルで洗浄した後、
真空乾燥してmu化合物を76零の収率で得た(純度7
2亀)。After filtering the precipitate and washing with isopropyl ether,
The mu compound was obtained by vacuum drying in a yield of 760 (purity 7).
2 turtles).
得られた化合物のIR及びNMRスペクトルは参考例1
で得られたものと一致した。The IR and NMR spectra of the obtained compound are shown in Reference Example 1.
It was consistent with what was obtained.
[参考例3]
アセトニトリル27.6+alとジメチルアセトアミド
1.54m1の混液を氷冷し、オキシ塩化リン1゜54
m1を加えて、同温30分間攪拌後−20℃に冷却し、
2−(2−トリチルアミノチアゾール−4−イル)−
2−メトキシイミノ酢酸リチウム塩2.50gを加え、
同温30分間攪拌する6反応混合液を濾取後真空乾燥し
て2.03gの活性体を得た。このうち1.40gを取
り。[Reference Example 3] A mixture of 27.6+al of acetonitrile and 1.54ml of dimethylacetamide was cooled on ice, and 1°54ml of phosphorus oxychloride was added.
m1 was added, stirred at the same temperature for 30 minutes, and then cooled to -20°C.
2-(2-tritylaminothiazol-4-yl)-
Add 2.50 g of 2-methoxyiminoacetic acid lithium salt,
The 6-reaction mixture was stirred at the same temperature for 30 minutes, collected by filtration, and dried under vacuum to obtain 2.03 g of the active substance. Take 1.40g of this.
アセトニトリル13.8a+1を加えて一20℃で懸濁
する。トリエチルアミン0.69m1.次いで7β−ア
ミノ−3−(4−(オキサゾール−5−イル)−1−ピ
リジニオコメチル−3−セフェム−4−カルボン酸p−
メトキシベンジルエステルホウフッ化物ホウフッ化水素
酸塩1.70gを加えた。水冷で30分間攪拌後、水に
注加し、析出物を濾取した。真空乾燥して得られた粉末
にトリフロロ酢酸30m1hアニソール3mlを加え、
水冷2時間攪拌した0反応後、イソプロピルエーテル9
0m1を加えて析出物を濾取し、イソプロピルエーテル
で洗浄した後、真空乾燥して標題化合物を89零の収率
で得た(純度87k)。Add 13.8a+1 acetonitrile and suspend at -20°C. Triethylamine 0.69ml1. Then 7β-amino-3-(4-(oxazol-5-yl)-1-pyridiniocomethyl-3-cephem-4-carboxylic acid p-
1.70 g of methoxybenzyl ester borofluoride borohydrofluoride was added. After stirring with water cooling for 30 minutes, it was poured into water, and the precipitate was collected by filtration. Add 30 ml of trifluoroacetic acid and 3 ml of anisole to the powder obtained by vacuum drying.
After cooling with water and stirring for 2 hours, isopropyl ether 9
After adding 0 ml of the precipitate, the precipitate was collected by filtration, washed with isopropyl ether, and then dried under vacuum to obtain the title compound in a yield of 89% (purity: 87k).
得られた化合物のIR及びNMRスペクトルは参考例1
で得られたものと一致した。The IR and NMR spectra of the obtained compound are shown in Reference Example 1.
It was consistent with what was obtained.
[参考例4]
アセトニトリル13.8mlとジメチルホルムアミド0
.64m1の混液を氷冷し、オキシ塩化リン0.77m
1を加えて同温30分間攪拌後−20℃に冷却し、 2
−(2−トリチルアミノチアゾール−4−イル)−2−
メトキシイミノ酢酸リチウム塩1.25gを加え、同温
30分間攪拌した。トリエチルアミン1.731111
.次いで7β−アミノ−3−[4−(オキサゾール−5
−イル)−1−ピリジニオコメチル−3−セフェム−4
−カルボン酸p−メトキシベンジルエステルホウフッ化
物ホウフッ化水素酸塩1.70gを加えた。水冷で30
分間攪拌後1反応液を木に注加し、析出物を濾取した。[Reference Example 4] 13.8 ml of acetonitrile and 0 ml of dimethylformamide
.. Cool 64 ml of the mixture on ice, and add 0.77 ml of phosphorus oxychloride.
Add 1 and stir for 30 minutes at the same temperature, then cool to -20°C,
-(2-tritylaminothiazol-4-yl)-2-
1.25 g of lithium methoxyiminoacetate was added and stirred at the same temperature for 30 minutes. Triethylamine 1.731111
.. Then 7β-amino-3-[4-(oxazole-5
-yl)-1-pyridiniocomethyl-3-cephem-4
-Carboxylic acid p-methoxybenzyl ester borofluoride 1.70 g of borohydrofluoride was added. 30 with water cooling
After stirring for a minute, one reaction solution was poured onto wood, and the precipitate was collected by filtration.
真空乾燥して得られた粉末にトリフロロ酢酸30m1と
アニソール3mlを加え、水冷2時間攪拌した0反応後
、イソプロピルエーテル90m1を加え、析出物を濾取
し、イソプロピルエーテルで洗浄した後。30 ml of trifluoroacetic acid and 3 ml of anisole were added to the powder obtained by vacuum drying, and the mixture was cooled with water and stirred for 2 hours. After the reaction, 90 ml of isopropyl ether was added, and the precipitate was collected by filtration and washed with isopropyl ether.
真空乾燥して標題化合物を86零の収率で得た(純度7
6零)。Vacuum drying gave the title compound in a yield of 860 (purity 7).
6 zero).
得られた化合物のIR及びNMRスペクトルは参考例1
で得られたものと一致した。The IR and NMR spectra of the obtained compound are shown in Reference Example 1.
It was consistent with what was obtained.
Claims (1)
−メトキシイミノ酢酸リチウム塩およびその水和物2-(2-tritylaminothiazol-4-yl)-2
-Methoxyiminoacetic acid lithium salt and its hydrates
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP63125471A JP2662414B2 (en) | 1988-05-23 | 1988-05-23 | Thiazole derivatives |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP63125471A JP2662414B2 (en) | 1988-05-23 | 1988-05-23 | Thiazole derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH01294667A true JPH01294667A (en) | 1989-11-28 |
| JP2662414B2 JP2662414B2 (en) | 1997-10-15 |
Family
ID=14910909
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP63125471A Expired - Fee Related JP2662414B2 (en) | 1988-05-23 | 1988-05-23 | Thiazole derivatives |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2662414B2 (en) |
-
1988
- 1988-05-23 JP JP63125471A patent/JP2662414B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP2662414B2 (en) | 1997-10-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4694079A (en) | 3-propenyl cephalosporin solvates | |
| EP0612751A2 (en) | Compounds for the preparation of cephem derivatives | |
| JPH027315B2 (en) | ||
| EP0264091B1 (en) | 3-propenylcephem derivative, preparation thereof, chemical intermediates therein, pharmaceutical composition and use | |
| JP3713282B2 (en) | Selective process for the Z isomer of 3- (2-substituted-vinyl) -cephalosporin | |
| JPS60169486A (en) | Preparation of 7-amino-3-substituted methyl-3-cephem-4- carboxylic acid and lower alkylsilyl derivative thereof | |
| JPWO1998058932A1 (en) | Selective preparation of Z isomers of 3-(2-substituted-vinyl)-cephalosporins | |
| JPS6360992A (en) | Novel oxime derivative of 3-substituted 7-aminothiazolylacetamide cephalosporinic acid | |
| JPH0246588B2 (en) | ||
| JP2867192B2 (en) | 7-acyl-3-substituted carbamoyloxycephem compounds and method for producing the same | |
| HU184882B (en) | Process for producing cepheme-carboxylic acid derivatives | |
| JP4022070B2 (en) | Novel thiazole compound and method for producing the same | |
| JP3115455B2 (en) | New cephalosporin derivatives | |
| CA1236089A (en) | Ceftazidime | |
| JPH0134227B2 (en) | ||
| EP0135258A2 (en) | Improvements in or relating to a crystalline 7-(R)-amino-3-(1-pyridiniummethyl)-ceph-3-em-4-carboxylate | |
| JP2662414B2 (en) | Thiazole derivatives | |
| CA2520083A1 (en) | Novel crystal of 7-[2-[(2-aminothiazol-4-yl)-2-hydroxyiminoacetamide-3-vinyl-3-cephem-4-carboxylic acid (syn isomer) and method for preparation thereof | |
| JPS6351389A (en) | Cephalosporin derivative, production thereof and composition having antimicrobial activity | |
| JPS6351388A (en) | Cephalosporin derivative, production thereof and composition having antimicrobial activity | |
| KR840002008B1 (en) | Method for preparing 7-acylamino-3-vinyl cephalosporan acid derivative | |
| KR0156275B1 (en) | Process for preparation of ceftazidime pentahydrate | |
| JPH0251555B2 (en) | ||
| JP2617618B2 (en) | Cefarosporin derivative | |
| KR930007816B1 (en) | New Preparation Method of Cefem Compound |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| LAPS | Cancellation because of no payment of annual fees |